Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
---|---|---|---|---|---|---|---|---|---|---|---|
INVA | Innoviva, Inc. | Ronsheim Matthew | See Remarks | Mar 05, 2024 | Option Exercise | $14.88 | 12,768 | 189,988 | 40,778 | Mar 07, 2024, 07:02 PM | |
INVA | Innoviva, Inc. | Ronsheim Matthew | See Remarks | Feb 20, 2024 | Option Exercise | $15.80 | 807 | 12,751 | 28,010 | Feb 22, 2024, 09:31 PM | |
INVA | Innoviva, Inc. | Ronsheim Matthew | See Remarks | Jan 18, 2024 | Option Exercise | $16.05 | 1,600 | 25,680 | 28,817 | Jan 22, 2024, 09:16 PM | |
ETTX | Entasis Therapeutics Holdings Inc. | Ronsheim Matthew | Chief of Pharma Sciences & MFG | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:09 PM | |
ETTX | Entasis Therapeutics Holdings Inc. | Ronsheim Matthew | Chief, Pharma Sciences & MFG. | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:05 PM | |
ETTX | Entasis Therapeutics Holdings Inc. | Ronsheim Matthew | See Remarks | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:05 PM |